Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor
1Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
2Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
3Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
4Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
5Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
6Institute for Anatomy, University of Duisburg-Essen, Essen, Germany
7DRG Instruments GmbH, Marburg, Germany
8Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
9Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 11, Pages 1504–1510, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: https://doi.org/10.1515/CCLM.2007.316, October 2007
- Published Online:
Background: Decreased concentrations of the circulating angiogenic factors, free placental growth factor (PLGF) and free vascular endothelial growth factor (VEGF), and increased concentrations of the anti-angiogenic factor, soluble fms-like tyrosine kinase 1 (sFLT-1) have been observed during clinical preeclampsia. We established a new PLGF-ELISA kit for the measurement of PLGF in sera. In the present study, we demonstrated the assay characteristics by measurement of PLGF expression in normal and preeclamptic pregnancies as compared to an established research kit.
Methods: Blood samples were taken from 64 women with singleton uncomplicated pregnancies for longitudinal measurement of PLGF in the course of pregnancy. In 30 preeclamptic patients, serum levels of PLGF and sFLT-1 were measured by Human PLGF-ELISA and Human sVEGF R1 ELISA according to the described test principles. The assay characteristics of the new PLGF-ELISA were determined and the results were compared to those performed with an available research kit.
Results: The PLGF concentration in normal pregnancies showed a steady increase starting at the beginning of the second trimester with a peak at 28–32 weeks and a consistent decline thereafter. The preeclamptic pregnancies had significant lower serum concentrations of PLGF and significant higher serum concentrations of sFLT-1 as compared to the non-preeclamptic pregnancies. All the measured assay characteristics fulfilled the required specifications. Comparison of the values of the new PLGF-ELISA and the established research kit resulted in a correlation coefficient of 0.921.
Conclusions: Our results support the hypothesis that an imbalance between factors promoting angiogenesis, such as PLGF, and factors antagonizing angiogenesis, such as sFLT-1, has a fundamental role in the pathogenesis of preeclampsia. The new established ELISA test can be considered reliable and it offers many advantages. As it is authorized for routine diagnostic testing, it may offer new possibilities in the prediction of preeclampsia in clinical routine.
Clin Chem Lab Med 2007;45:1504–10.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.